Vnitr Lek 2017, 63(1):37-40 | DOI: 10.36290/vnl.2017.007

Treatment of HCV genotype 2 infection

Petr Husa^*, Petr Husa jr

Klinika infekčních chorob LF MU a FN Brno, pracoviště Bohunice

Introduction:
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide.

Aims:
Retrospectively evaluate the results of therapy of patients with genotype 2 HCV treated during last 15 years at the Department of Infectious Diseases University Hospital Brno and Faculty of Medicine Masaryk University Brno, Czech Republic.

Patients and methods:
15 patients (9 men, 6 women, mean age 54.73 ± 13.83 years, median 54 years) with chronic genotype 2 infection were treated at in our department during last 15 years. It is the biggest group of patients with this diagnosis treated in the Czech Republic. Proportion of genotype 2 subtypes was following: 1 times subtype 2a, 2 times subtype 2a/2c, 5 times subtype 2b, in the rest 7 cases only genotype 2 was determined without possibility to determinate subtype.

Results:
9 patients were treated with the combination of peginterferon α-2a (180 μg once weekly subcutaneously) and ribavirin (1 000 or 1 200 mg daily according to the weight) for 24 weeks in the years 2002-2015, sustained virological response (SVR) achieved 6 of them (67 %). Two relapses and one breakthrough were recorded. 7 patients were treated with combination of sofosbuvir (400 mg daily) and ribavirin (1 000 or 1 200 mg daily according to the weight) for 12 weeks in the years 2015-2016 - 6 of them were treatment naïve, one after breakthrough in previous therapy. All of these 7 patients achieved SVR (100 %).

Conclusions:
Genotype 2 therapy still not represents serious therapeutic problem. The number of difficultly treatable patients is gradually increasing in many well-developed countries during last several years. However the therapeutic possibilities are quickly developing.

Keywords: chronic hepatitis C; genotype 2; pegylated interferon; ribavirin; sofosbuvir

Received: October 26, 2016; Accepted: December 7, 2016; Published: January 1, 2017  Show citation